AngioDynamics (NASDAQ:ANGO) Sets New 12-Month High – Here’s What Happened

AngioDynamics, Inc. (NASDAQ:ANGO) hit a new 52-week high on Monday . The company traded as high as $15.73 and last traded at $15.5250, with a volume of 405873 shares changing hands. The stock had previously closed at $15.69.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ANGO shares. Zacks Research downgraded AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. HC Wainwright lifted their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Canaccord Genuity Group boosted their price objective on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $19.50.

AngioDynamics Stock Performance

The business’s fifty day simple moving average is $13.35 and its 200-day simple moving average is $11.76. The firm has a market cap of $650.95 million, a P/E ratio of -18.10 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.04. The firm had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Analysts anticipate that AngioDynamics, Inc. will post -0.25 earnings per share for the current year.

Insiders Place Their Bets

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On AngioDynamics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC lifted its stake in AngioDynamics by 146.4% in the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 1,199 shares during the period. Kemnay Advisory Services Inc. purchased a new position in AngioDynamics during the 4th quarter valued at $27,000. State of Wyoming purchased a new position in AngioDynamics during the 2nd quarter valued at $31,000. Russell Investments Group Ltd. raised its holdings in AngioDynamics by 329.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 3,213 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in AngioDynamics by 359.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 4,268 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.